Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 1, 2006, Pages 41-50

  Sugimoto, Mitsushige ^a,b   Furuta, Takahisa ^a,b   Shirai, Naohito ^a,b   Ikuma, Mutsuhiro ^a,b   Hishida, Akira ^a,b   Ishizaki, Takashi ^a,b  

^a First Department of Medicine   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; GASTRITIS; GENOTYPE; HELICOBACTER PYLORI; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; PROTON PUMPS; STOMACH ULCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745412138     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.03.007     Document Type: Article

References (44)

1. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (2001) 784-789
2. Hopkins R.J., Girardi L.S., and Turney E.A. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence. a review. Gastroenterology 110 (1996) 1244-1252
3. Wotherspoon A.C., Doglioni C., de Boni M., Spencer J., and Isaacson P.G. Antibiotic treatment for low-grade gastric MALT lymphoma. [letter]. Lancet 343 (1994) 1503
4. Gasbarrini A., Franceschi F., Tartaglione R., Landolfi R., Pola P., and Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. [letter]. Lancet 352 (1998) 878
5. Tebbe B., Geilen C.C., Schulzke J.D., Bojarski C., Radenhausen M., and Orfanos C.E. Helicobacter pylori infection and chronic urticaria. J Am Acad Dermatol 34 (1996) 685-686
6. Treiber G., and Lambert J.R. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 93 (1998) 1080-1084
7. Asaka M., Sugiyama T., Kato M., Satoh K., Kuwayama H., Fukuda Y., et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6 (2001) 254-261
8. Furuta T., Shirai N., Takashima M., Xiao F., Hanai H., Sugimura H., et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69 (2001) 158-168
9. Grayson M.L., Eliopoulos G.M., Ferraro M.J., and Moellering Jr. R.C. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 8 (1989) 888-889
10. Goddard A.F., Jessa M.J., Barrett D.A., Shaw P.N., Idstrom J.P., Cederberg C., et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111 (1996) 358-367
11. Scott D.R., Weeks D., Hong C., Postius S., Melchers K., and Sachs G. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 114 (1998) 58-70
12. Labenz J., Stolte M., Blum A.L., Jorias I., Leverkus F., Sollbohmer M., et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication. a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 37 (1995) 39-43
13. Shirai N., Furuta T., Moriyama Y., Okochi H., Kobayashi K., Takashima M., et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15 (2001) 1929-1937
14. Sugimoto M., Furuta T., Shirai N., Kajimura M., Hishida A., Sakurai M., et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to CYP2C19 genotype status. Clin Pharmacol Ther 76 (2004) 290-301
15. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31 (1996) 9-28
16. Wolfe M.M., and Nompleggi D.J. Cytokine inhibition of gastric acid secretion-a little goes a long way. Gastroenterology 102 (1992) 2177-2178
17. Kondo S., Shinomura Y., Kanayama S., Kawabata S., Miyazaki Y., Imamura I., et al. Interleukin-1 beta inhibits gastric histamine secretion and synthesis in the rat. Am J Physiol 267 (1994) G966-G971
18. Takashima M., Furuta T., Hanai H., Sugimura H., and Kaneko E. Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut 48 (2001) 765-773
19. Wang M., Furuta T., Takashima M., Futami H., Shirai N., Hanai H., et al. Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J Gastroenterol 34 Suppl 11 (1999) 10-17
20. Furuta T., El-Omar E.M., Xiao F., Shirai N., Takashima M., and Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 123 (2002) 92-105
21. Machado J.C., Pharoah P., Sousa S., Carvalho R., Oliveira C., Figueiredo C., et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121 (2001) 823-829
22. Furuta T., Shirai N., Xiao F., El-Omar E.M., Rabkin C.S., Sugimura H., et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2 (2004) 22-30
23. Sugimoto M., Furuta T., Shirai N., Nakamura A., Xiao F., Kajimura M., et al. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J Gastroenterol Hepatol (2006) In press
24. Negoro K., Kinouchi Y., Hiwatashi N., Takahashi S., Takagi S., Satoh J., et al. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. Gastroenterology 117 (1999) 1062-1068
25. Ohyama I., Ohmiya N., Niwa Y., Shirai K., Taguchi A., Itoh A., et al. The association between tumour necrosis factor-alpha gene polymorphism and the susceptibility to rugal hyperplastic gastritis and gastric carcinoma. Eur J Gastroenterol Hepatol 16 (2004) 693-700
26. Hamajima N., Shibata A., Katsuda N., Matsuo K., Ito H., Saito T., et al. Subjects with TNF-A-857TT and -1031TT genotypes showed the highest Helicobacter pylori seropositive rate compared with those with other genotypes. Gastric Cancer 6 (2003) 230-236
27. Miyazoe S., Hamasaki K., Nakata K., Kajiya Y., Kitajima K., Nakao K., et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 97 (2002) 2086-2092
28. Dent J.C., and McNulty C.A. Evaluation of a new selective medium for Campylobacter pylori. Eur J Clin Microbiol Infect Dis 7 (1988) 555-558
29. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
30. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269 (1994) 15419-15422
31. Ishiguro A., Kubota T., Soya Y., Sasaki H., Yagyu O., Takarada Y., et al. High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal Biochem 337 (2005) 256-261
32. Tarlow J.K., Blakemore A.I., Lennard A., Solari R., Hughes H.N., Steinkasserer A., et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91 (1993) 403-404
33. Murakami K., Sato R., Okimoto T., Nasu M., Fujioka T., Kodama M., et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16 (2002) 1933-1938
34. Ducons J.A., Santolaria S., Guirao R., Ferrero M., Montoro M., and Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori. a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 13 (1999) 775-780
35. de Boer W.A. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 22 (1996) 313-316
36. Prinz C., Neumayer N., Mahr S., Classen M., and Schepp W. Functional impairment of rat enterochromaffin-like cells by interleukin 1 beta. Gastroenterology 112 (1997) 364-375
37. Queiroz D.M., Mendes E.N., Rocha G.A., Moura S.B., Resende L.M., Cunha-Melo J.R., et al. Histamine content of the oxyntic mucosa from duodenal ulcer patients. effect of Helicobacter pylori eradication. Am J Gastroenterol 88 (1993) 1228-1232
38. Beales I.L., and Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 42 (1998) 227-234
39. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
40. Hwang I.R., Kodama T., Kikuchi S., Sakai K., Peterson L.E., Graham D.Y., et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 123 (2002) 1793-1803
41. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes. an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 (1991) 1209-1220
42. Nelson D.R., Lauwers G.Y., Lau J.Y., and Davis G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C. a pilot trial of interferon nonresponders. Gastroenterology 118 (2000) 655-660
43. Furuta T., Shirai N., Xiao F., Takashita M., Sugimoto M., Kajimura M., et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50 (2003) 2274-2278
44. Furuta T., Takashima M., Shirai N., Xiao F., Hanai H., Ohashi K., et al. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 67 (2000) 684-689